Tevogen Bio to Present Preclinical Data of TVGN-489, its Investigational Allogeneic Cytotoxic T Cell Therapy for COVID-19, at the 2021 Annual Meeting of American Association of Immunologists
METUCHEN, N.J.--(BUSINESS WIRE)--#COVID19--Tevogen Bio, a pioneering immunotherapy company, announces that Dr. Neal Flomenberg, MD, Professor and Chairman of the Department of Medical Oncology at Thomas Jefferson University, will present preclinical data of TVGN-489, Tevogen’s investigational allogeneic cytotoxic T cell therapy for COVID-19 at the 2021 Annual Meeting of the American Association of Immunologists (AAI). AAI’s Annual Meeting will convene virtually May 10-15.
Dr. Dolores Grosso, the Primary Investigator of the proof of concept clinical trial of TVGN-489, expressed optimism regarding these initial results. “The preclinical data regarding TVGN-489 is highly encouraging and represents a major milestone in the development of this promising therapy,” Dr. Grosso stated.
Details of the presentation at AAI’s Virtual Immunology 2021 are as follows:
Presentation Title: TVGN-489: A novel approach for the production of SARS-CoV-2-specific cytotoxic T lymphocytes to treat COVID-19
Session Name: Technological Innovation II (Interesting Tech Development)
Session Date: Monday, May 10, 2021
Presentation Time: 1:00 pm
Presenters: Dr. Neal Flomenberg, MD, Professor and Chairman of the Department of Medical Oncology at Thomas Jefferson University
Abstract Number: 303
About Tevogen Bio™
Tevogen Bio was formed after decades of research by its contributors to concentrate and leverage their expertise, spanning multiple sectors of the healthcare industry, to help address some of the most common and deadly illnesses known today. The company’s mission is to provide curative and preventative treatments that are affordable and scalable, in order to positively impact global public health.
About Dr. Neal Flomenberg
Dr. Neal Flomenberg is the Chairman of the Department of Medical Oncology and Deputy Director of the Sidney Kimmel Cancer Center at Jefferson University in Philadelphia. Dr. Flomenberg launched Jefferson’s Blood and Marrow Transplantation (BMT) Program in 1995. Throughout his four decades of practice, he has maintained a longstanding interest in the immunogenetics and immunology of stem cell transplantation, with the goal of making transplantation safer and more widely available. He is board certified in the fields of internal medicine, hematology, and medical oncology.
Forward Looking Statements
This press release contains certain forward-looking statements relating to Tevogen Bio™ Inc.’s (the “Company”) development and patient access of its innovations in infectious diseases and oncology. These statements are based on management’s current expectations and beliefs as of the date of this release and are subject to a number of factors which involve known and unknown risks, delays, uncertainties and other factors not under the company’s control which may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations implied by these forward-looking statements. In any forward-looking statement in which the Company expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These factors include results of current or pending clinical trials, risks associated with intellectual property protection, financial projections, sales, pricing and actions by the FDA/EMA. The Company undertakes no obligation to update the forward-looking statements or any of the information in this release, or provide additional information, and expressly disclaims any and all liability and make no representations or warranties in connection herewith or with respect to any omissions herefrom.